#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Hepato-lenticular degeneration Arteriovenous malformation Fatty acid oxidation disorder Pustular psoriasis Mantle cell lymphoma stage II Asthma Spinal cord injury cervical Cluster headache Retinopathy of prematurity Factor VIII deficiency Paraganglion neoplasm Non-Hodgkin's lymphoma Intracranial calcification Transferrin decreased Encephalopathy neonatal More trials…

    Learn about Rare Diseases

    Metachromatic leukodystrophy Mantle cell lymphoma stage II – Diagnostics Gastrointestinal stromal tumour – Life with Disease Kearns-Sayre syndrome – Diagnostics Ewing’s sarcoma recurrent – Life with Disease Waldenstrom’s macroglobulinaemia – Treatment Hereditary hypophosphataemic rickets – Treatment Bronchopulmonary dysplasia Short-bowel syndrome – Treatment Richter’s syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Perindopril Tert-Butylamine Dried Ferrous Sulfate Prilocaine Osilodrostat Inavolisib Lansoprazole Mesenchymal Cells Rotigotine Mometasone Dextran 70 Sodium AZD5148 [68GA]GA-NOTA-AE105 Salmeterol Ecubectedin A/(H3N2)-LIKE VIRUS ANTIGEN Paraffin White Soft Linaclotide Zagociguat Imipenem More therapies…

    Learn about Your Condition

    Pyoderma gangrenosum Chronic disease Papulopustular rosacea Haemorrhage prophylaxis Thymoma malignant CADASIL Neurodegenerative disorder Actinic keratosis Arthralgia Plasma cell leukaemia Impaired gastric emptying Post-acute COVID-19 syndrome Immune thrombocytopenia Small intestine leiomyosarcoma Left ventricular failure More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Laiko General Hospital Of Athens

Laiko General Hospital Of Athens

Messogion Avenue 154, Athens, 115 27, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study comparing firmonertinib with osimertinib or afatinib for patients with advanced lung cancer with uncommon EGFR mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Afatinib
    • N-[2-[2-(Dimethylamino)Ethyl-Methylamino]-5-[[4-(1-Methylindol-3-Yl)Pyrimidin-2-Yl]Amino]-6-(2,2,2-Trifluoroethoxy)Pyridin-3-Yl]Prop-2-Enamide
    • Osimertinib
    France Greece Italy Spain

  • A study to evaluate the safety of dazodalibep in patients with Sjögren’s Syndrome over a long period of time

    Recruiting

    3 1 1
    Investigated Drugs:
    • Dazodalibep
    Belgium Croatia Denmark France Germany Greece +6

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • Testing MK-2870 with pembrolizumab compared to pembrolizumab alone after surgery in patients with non-small cell lung cancer who did not respond fully to treatment

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Buclizine Hydrochloride
    • Carboplatin
    • Cisplatin
    Austria Belgium Czechia France Germany Greece +7

  • A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

    Recruiting

    2 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • SPY002
    Austria Belgium Bulgaria Croatia Czechia France +10

  • A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A study testing duvakitug for patients with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • A Study of Autologous Urothelial Cell Treatment with Bioprinter During Bladder Reconstruction Surgery in Patients with Muscle-Invasive Bladder Cancer

    Recruiting

    1 1 1
    Investigated Drugs:
    • AUROCELL-TX
    Greece

  • Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

    Recruiting

    3 1
    Investigated Drugs:
    • ZILEBESIRAN
    Austria Belgium Bulgaria Czechia Denmark France +11

  • Long-term Safety Study of Vusolimogene Oderparepvec, RP2, and RP3 in Patients with Melanoma, Liver Cancer, or Advanced Solid Tumors

    Recruiting

    3 1 1
    Investigated Drugs:
    • Vusolimogene Oderparepvec
    • RP2
    • RP3
    France Germany Greece Poland Spain
Previous Page
1 … 3 4 5 6 7 … 38
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!